A study from the Abramson Family Cancer Research Institute, Philadelphia, USA; and Howard Hughes Medical Institute, Philadelphia, USA shows that “Fructose-1,6-bisphosphatase opposes renal carcinoma progression.”
This study was published in the Journal Nature (September, 2014) by Prof. M. Celeste Simon, Li B0 [I.F >42] and others from the Abramson Family Cancer Research Institute, Philadelphia, USA, Howard Hughes Medical Institute, Philadelphia, USA.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: NIDDM drugs as Anti-cancer drugs: Metformin increases the expression of tumor suppressor Fructose-1,6-bisphosphatase (FBP1) via up regulation of its target gene. This study may suggest that Metformin, by up regulating its target gene, it may induce FBP1. Thereby, it may inhibit (1) the expression of hypoxia-inducible factor (HIF-1); (2) glycolysis; and (3) the progression of renal cell carcinoma. Together, this study suggests that pharmacological formulations encompassing “Metformin or its analogues“ can be used either in patients with renal cell carcinoma or with both T2DM and renal cell carcinoma.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., NIDDM drugs as Anti-cancer drug: Metformin increases the expression of tumor suppressor Fructose-1,6-bisphosphatase (FBP1) via up regulation of its target gene, 20/September/2014, 04.36 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
